References

2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension

10.1183/13993003.00879-2022 · 2023 · External reference

Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease

10.1016/j.jacc.2022.05.038 · 2022 · External reference

Review of 2022 WHO guidelines on the control and elimination of schistosomiasis

10.1016/s1473-3099(22)00221-3 · 2022 · External reference

Schistosomiasis pulmonary arterial hypertension

10.3389/fimmu.2020.608883 · 2020 · External reference

Characteristic sonographic features of schistosomal periportal fibrosis

10.2214/ajr.143.1.69 · 1984 · External reference

The causal role of IL-4 and IL-13 in schistosoma mansoni pulmonary hypertension

10.1164/rccm.201410-1820oc · 2015 · External reference

Portopulmonary hypertension: results from a 10-year screening algorithm

10.1002/hep.21431 · 2006 · External reference

Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease

10.1164/rccm.200809-1472oc · 2009 · External reference

The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis

10.1111/liv.13589 · 2018 · External reference

Shear stress-exposed pulmonary artery endothelial cells fail to upregulate HSP70 in chronic thromboembolic pulmonary hypertension

10.1371/journal.pone.0242960 · 2020 · External reference

Main pulmonary arterial wall shear stress correlates with invasive hemodynamics and stiffness in pulmonary hypertension

10.1086/685024 · 2016 · External reference

Portopulmonary hypertension: from bench to bedside

10.3389/fmed.2020.569413 · 2020 · External reference

Estrogen signaling and portopulmonary hypertension: the pulmonary vascular complications of liver disease study (PVCLD2)

10.1002/hep.31314 · 2021 · External reference

Treatment of portopulmonary hypertension (PoPH): a review

10.1016/j.liver.2022.100071 · 2022 · External reference

Schistosomiasis-associated pulmonary arterial hypertension: a systematic review

10.1183/16000617.0089-2019 · 2020 · External reference

Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups

10.1111/j.1600-6143.2008.02384.x · 2008 · External reference

Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol

10.1002/lt.21174 · 2007 · External reference

Portopulmonary hypertension in the current era of pulmonary hypertension management

10.1016/j.jhep.2020.02.021 · 2020 · External reference

Hemostatic dysfunction is increased in patients with hepatosplenic schistosomiasis mansoni and advanced periportal fibrosis

10.1371/journal.pntd.0002314 · 2013 · External reference

Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study

10.1007/s12072-022-10456-y · 2023 · External reference

Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study

10.1155/2021/5595614 · 2021 · External reference

COR pulmonale due to chronic infestation with schistosoma haematobium

1964 · External reference

TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension

10.1038/ncomms15494 · 2017 · External reference

Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni

10.1161/circulationaha.113.003072 · 2013 · External reference

Morbidity and mortality due to Schistosoma mansoni related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review

10.3390/tropicalmed5010020 · 2020 · External reference

Noninvasive prediction of large esophageal varices in chronic liver disease patients

10.4103/1319-3767.58767 · 2010 · External reference

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

10.1002/hep.21907 · 2007 · External reference

Pulmonary arterial hypertension caused by congenital extrahepatic portocaval shunt: a case report

10.1186/s12872-019-1124-1 · 2019 · External reference

Cardiopulmonary manifestations of portovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation

10.1111/j.1399-3046.2010.01355.x · 2011 · External reference

Congenital absence of the portal vein as a rare cause of portopulmonary hypertension-a case study series

2022 · External reference

Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension

10.1164/rccm.201807-1236oc · 2019 · External reference

Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension

10.4103/2045-8932.110445 · 2013 · External reference

Role of soluble endoglin in BMP9 signaling

10.1073/pnas.1816661116 · 2019 · External reference

TGF beta and IL13 in Schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups

10.1186/1471-2334-14-282 · 2014 · External reference

Hypercoagulability in pulmonary hypertension

10.1016/j.ccm.2018.04.005 · 2018 · External reference

Histometrical investigation of the pulmonary artery in severe hepatic disease

10.1002/path.1711430106 · 1984 · External reference

Coexistent pulmonary and portal hypertension: morphologic and clinical features

10.1016/s0735-1097(87)80123-7 · 1987 · External reference

Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension

10.4103/2045-8932.93544 · 2011 · External reference

Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil

2019 · External reference

Cardiopulmonary manifestations of hepatosplenic schistosomiasis

10.1161/circulationaha.108.803221 · 2009 · External reference

Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension

10.1016/j.jinf.2013.08.004 · 2014 · External reference

Th2 CD4+ T cells are necessary and sufficient for schistosoma-pulmonary hypertension

10.1161/jaha.119.013111 · 2019 · External reference

Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension

10.1186/s12890-015-0115-y · 2015 · External reference

Hughes-Stovin syndrome

10.1186/1750-1172-6-15 · 2011 · External reference

Behçet’s syndrome: pulmonary vascular disease

10.1097/bor.0000000000000131 · 2015 · External reference

Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry

10.1111/imj.14751 · 2021 · External reference

Long-term outcome in liver transplantation candidates with portopulmonary hypertension

10.1002/hep.28990 · 2017 · External reference

Does portopulmonary hypertension impede liver transplantation in cirrhotic patients? A French multicentric retrospective study

10.1097/tp.0000000000001981 · 2018 · External reference

Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension

10.1093/cvr/cvw070 · 2016 · External reference

Evidence of pulmonary vascular reverse remodeling after pulmonary artery banding performed in early infancy in patients with congenital heart defects

10.1253/circj.cj-17-0379 · 2018 · External reference

Effect of specific therapy on the prevention and reversal of severe forms of schistosomiasis

10.1590/s0074-02761987000800062 · 1987 · External reference

Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies

10.1016/s0001-706x(00)00125-x · 2000 · External reference

The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension

10.1378/chest.11-0483 · 2012 · External reference

Persistent schistosomal pulmonary hypertension in a patient after reversion of a hepato-splenic form: presentation of a case

10.1590/s0037-86821986000300009 · 1986 · External reference

HIV and Schistosoma co-exposure leads to exacerbated pulmonary endothelial remodeling and dysfunction associated with altered cytokine landscape

10.3390/cells11152414 · 2022 · External reference

STELLAR trial investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension

10.1056/nejmoa2213558 · 2023 · External reference

PULSAR trial investigators. Sotatercept for the treatment of pulmonary arterial hypertension

10.1056/nejmoa2024277 · 2021 · External reference